NCT00950911 - Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

April 30, 2012

Conditions

Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Interventions

DRUG

amg 162

120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.

Trial Locations (17)

377 01

Research Site, Jindřichův Hradec

767 55

Research Site, Kroměříž

775 20

Research Site, Olomouc

110 00

Research Site, Prague

140 00

Research Site, Prague

140 44

Research Site, Prague

150 06

Research Site, Prague

160 00

Research Site, Prague

762 75

Research Site, Zlín

PO19 4SE

Research Site, Chichester

LS9 7TF

Research Site, Leeds

SE1 9RT

Research Site, London

W2 1NY

Research Site, London

M20 4BX

Research Site, Manchester

HA6 2RN

Research Site, Northwood

PE3 9GZ

Research Site, Peterborough

YO31 8HE

Research Site, York